Tumor angiogenesis: Past, present and the near future

Carcinogenesis

Volumn 21, Issue 3, 2000, Pages 505-515

  Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CAI; CGS 27023A; CILENGITIDE; CISPLATIN; COMBRETASTATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PURINE DERIVATIVE; SQUALAMINE; THALIDOMIDE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; ZK 2284;

ANGIOGENESIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 0034092011     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.3.505     Document Type: Review

References (166)

1. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
2. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175, 409-416.
3. Algire, G.H. and Chalkley, H.W. (1945) Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic implants. J. Natl Cancer Inst., 6, 73-85.
4. Greenblatt, M. and Shubi, P. (1968) Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl Cancer Inst., 41, 111-124.
5. Warren, B.A. and Shubik, P. (1966) The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab. Invest., 15, 464-478.
6. Folkman, J., Merler, E., Abernathy, C. and Williams, G. (1971) Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 133, 275-288.
7. Folkman, J. (1974) Tumor angiogenesis factor. Cancer Res., 34, 2109-2113.
8. Nelson, N.J. (1999) Angiogenesis research is on fast forward. J. Natl Cancer Inst., 91, 820-822.
9. Twardowski, P. and Gradishar, W.J. (1997) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol., 9, 584-589.
10. Nelson, N.J. (1998) Inhibitors of angiogenesis enter phase III testing. J. Natl Cancer Inst., 90, 960-963.
11. Hawkins, M.J. (1995) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol., 7, 90-93.
12. Gasparini, G. and Presta, M. (1996) Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann. Oncol., 7, 441-444.
13. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J. and Klagsbrun, M. (1984) Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science, 223, 1296-1299.
14. Folkman, J. and Klagsbrun, M. (1987) Angiogenic factors. Science, 235, 442-447.
15. Klagsbrun, M. and Soker, S. (1993) VEGF/VPF: the angiogenesis factor found? Curr. biol., 3, 699-702.
16. Sellke, F.W., Laham, R.J., Edelman, E.R., Pearlman, J.D. and Simons, M. (1998) Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg., 65, 1540-1544.
17. Tsurumi, Y., Kearney, M., Chen, D., Silver, M., Takeshita, S., Yang, J., Symes, J.F. and Isner, J.M. (1997) Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation. 96 (suppl. II), 382-388.
18. Schumacher, B., von Specht, B.U., Haberstroh, J. and Pecher, P. (1998) The stimulation of neo-angiogenesis in the ischemic heart by the human growth factor FGF. J. Cardiovasc. Surg., 39, 445-153.
19. Veikkola, T. and Alitalo, K. (1999) VEGFs, receptors and angiogenesis. Semin. Cancer biol., 9, 211-220.
20. Senger, D.R., Van De Water, L., Brown, L.F., Nagy, J.A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R.W., Dvorak, A.M. and Dvorak, H.F. (1993) Vascular permeability factor (VPE, VEGF) in tumor biology. Cancer Melasiasis Rev., 12, 303-324.
21. Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol., 146, 1029-1039.
22. Ferrara, N. and Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocr. Rev., 18, 4-25.
23. Ferrara, N. (1999) Vascular endothelial growth factor: molecular and biological aspects. Curr Top. Microbiol. Immunol., 237, 1-30.
24. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J. and Keshet, E. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med., 1, 1024-1028.
25. Benjamin, L.E. and Keshet, E. (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA, 94, 8761-8766.
26. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. and Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest., 103, 159-165.
27. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. and Ferrera, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
28. Witte, L., Hicklin, D.J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P. and Bohlen, P. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., 17, 155-161.
29. Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13, 9-22.
30. Zhu, Z., Rockwell, P., Lu, D., Kotanides, H., Pytowski, B., Hicklin, D.J., Bohlen, P. and Witte, L. (1998) Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res., 58, 3209-3214.
31. Schlaeppi, J.M., Siemeister, G., Weindel, K., Schnell, C. and Wood, J. (1999) Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J. Cancer Res. Clin. Oncol., 125, 336-342.
32. Presta, L.G., Chen, H., O'Connor, S.J., Chisholm, V, Meng, Y.G., Krummen, L., Winkler, M. and Ferrara, N. (1997) Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57, 4593-4599.
33. Ramakrishnan, S., Olson, T.A., Bautch, V.L. and Mohanraj, D. (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56, 1324-1330.
34. Shawver, L.K., Lipson, K.E., Fong, T.A.T., McMahon, G., Plowman, G.D. and Strawn, L.M. (1997) Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Dev. Trends, 2, 50-63.
35. Seo, M.S., Kwak, N., Ozaki, H., Yamada, H., Okamoto, N., Yamada, E., Fabbro, D., Hofmann, F., Wood, J.M. and Campochiaro, P.A. (1999) Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol., 154, 1743-1753.
36. Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-mitialed angiogenesis. Nature, 359, 843-845.
37. Ikeda, E., Achen, M.G., Breier, G. and Risau, W. (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem., 270, 19761-19766.
38. Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W. and Giaccia, A.J. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88-91.
39. Davis, S. and Yancopoulos, G.D. (1999) The angiopoietins: Yin and Yang in angiogenesis. Curr. Top. Microbiol. Immunol., 237, 173-185.
40. Korpelainen, E.I. and Alitalo, K. (1998) Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol., 10, 159-164.
41. Dumont, D.J., Yamaguchi, T.P., Conlon, R.A., Rossant, J. and Breitman, M.L. (1992) tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene, 7, 1471-1480.
42. Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Vivek, J., Ryan, T., Bruno, J., Radjiewski, C., Maisonpierre, P.C. and Yancopoulos, G.D. (1996) Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87, 1161-1169.
43. Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N. and Yancopoulos, G.D. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 1171-1180.
44. Maisonpierre, P.C., Suri, C., Jones, P.F. et al. (1997) Angiopoietin-2. a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60.
45. Holash, J., Maisonpierre, P.C., Compton, D., Boland, P., Alexander, C.R., Zagzag, D., Yancopoulos, G.D. and Wiegand, S.J. (1999) Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science, 284, 1994-1998.
46. Hanahan, D. (1997) Signaling vascular morphogenesis and maintenance. Science, 111, 48-50.
47. Fong, T.A., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K.P. and McMahon, G. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res., 59, 99-106.
48. Fearon, E.R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
49. Bouck, N., Stellmach, V. and Hsu, S.C. (1996) How tumors become angiogenic. Adv. Cancer Res., 69, 135-174.
50. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
51. Folkman, J. (1995) Angiogenesis inhibitors generated by tumors. Mol. Med., 1, 120-122.
52. Dameron, K.M., Volpert, O.V., Tainsky, M.A. and Bouck, N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582-1584.
53. Tolsma, S.S., Volpert, O.V., Good, D.J., Frazier, W.A., Polverini, P.J. and Bouck, N. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell. Biol., 122, 497-511.
54. Dvorak, H.F. and Gresser, I. (1989) Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumours in mice. J. Natl Cancer Inst., 81, 497-502.
55. Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N. and Fidler, I.J. (1995) Interferons a and p down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl Acad. Sci. USA, 92, 4562-4566.
56. Ezekowitz, R.A., Mulliken, J.B. and Folkman, J. (1992) Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med., 326, 1456-1463.
57. Clapp, C., Martial, A., Guzman, R.C., Rentier-Delrue, F. and Weiner, R.I. (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology, 133, 1292-1299.
58. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, S.W., Cao, Y., Sage, E.H. and Folkman, J. (1994) Angiostatin: a novel angiogenesis inhihitor that mediates the suppression of melastases by a Lewis lung carcinoma. Cell, 79, 315-328.
59. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
60. Zhai, Y., Ni, J., Jiang, G.W., Lu, J., Xing, L., Lincoln, C., Carter, K.C., Janat, F., Kozak, D., Xu, S., Rojas, L., Aggarwal, B.B., Ruben, S., Li, L.Y., Gentz, R. and Yu, G.L. (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J., 13, 181-189.
61. Pike, S.E., Yao, L., Jones, K.D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G. and Tosato, G. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med., 188, 2349-2356.
62. Vazquez, F., Hastings, G., Ortega, M.A., Lane, T.F., Oikemus, S., Lombardo, M. and Iruela-Arispe, M.L. (1999) METH-1, a human ortholog of ADAMTS-1 and METH-2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem., 274, 23349-23357.
63. Gupta, S.K., Hassel, T. and Singh, J.P. (1995) A potent inhibitor of endothelial cell proliferation is generated by proteolylic cleavage of the chemokine platelet factor 4. Proc. Nalt Acad. Sci. USA, 92, 7799-7803.
64. O'Reilly, M.S., Pirie-Shepherd, S., Lane, W.S. and Folkman, J. (1999) Antiangiogenic activity of the cleaved conformation of the Serpin Antithrombin III.Science, 285, 1926-1928.
65. Sage, E.H. (1999) Pieces of eight: bioactive fragments of extracellular ptoeins as regulators of angiogenesis. Trends Biol. Sci., 1, 182.
66. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Sasazuki, T. and Kerbel, R.S. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55, 4575-4580.
67. Viloria-Petit, A.M., Rak, J., Hung, M.-C., Rockwell, P., Goldstein, N. and Kerbel, R.S. (1997) Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151, 1523-1530.
68. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B.Y., Hicklin, D.J., Radinsky, R. and Dinney, C.P. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5, 257-265.
69. Kerbel, R.S., Viloria-Petit, A.M., Okada, F. and Rak, J.W. (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol. Med., 4, 286-295.
70. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G. and Marme, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res., 56, 2299-2301.
71. Wizigmann-Voos, S., Breier, G., Risau, W. and Plate, K.H. (1995) Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res., 55, 1358-1364.
72. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79, 1157-1164.
73. Stromblad, S. and Chercsh, D.A. (1996) Cell adhesion and angiogenesis. Trends Cell Biol. 6, 462.
74. Bischoff, J. (1995) Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol, 5, 69-73.
75. Burrows, F.J., Derbyshire, E.J., Tazzari, P.L., Amlot, P. Gazdar, A.F., King, S.W., Letarte, M., Vitetta, E.S. and Thorpe, P.E. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1, 1623-1634.
76. Chang, S.S., Reuter, V.E., Heston, W.D., Bander, N.H., Grauer, L.S. and Gaudin, P.B. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associaled neovasculalure. Cancer Res., 59, 3192-3198.
77. Castellani, P. Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G. and Zardi, L. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer, 59, 612-618. [Published erratum appears in Int. J. Cancer (1995), 62, 118.]
78. Neri, D., Camemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., Zardi, L. and Winter, G. (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol., 15, 1271-1275.
79. Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D. and Zardi, L. (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood, 94, 192-198.
80. Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R. and Weiss, S.J. (1998) Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 95, 365-377.
81. Folkman, J. and Haudenschild, C. (1980) Angiogenesis in vitro. Nature, 288, 551-555.
82. Jain, R.K., Schlenger, K., Hockel, M. and Yuan, F. (1997) Quantitative angiogenesis assays: progress and problems. Nature Med., 3, 1203-1208.
83. Passaniti, A., Taylor, R.M., Pili, R., Guo, Y., Long, P.V., Haney, J.A., Pauly, R.R., Grant, D.S. and Martin, G.R. (1992) Methods in laboratory investigation: a simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab. Invest., 67, 519.
84. Parish, C.R., Freeman, C., Brown, K.J., Francis, D.J. and Cowden, W.B. (1999) Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res., 59, 3433-3441.
85. Weidner, N., Semple, J.P., Welch, W.R. and Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med., 324, 1-8.
86. Weidner, N. (1995) Intramural microvessel density as a prognostic factor in cancer. Am. J. Pathol, 147, 9-19.
87. Rak, J., St Croix, B. and Kerbel, R.S. (1995) Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs, 6, 3-18.
88. Rak, J.W., Hegmann, E.J., Lu, C. and Kerbel, R.S. (1994) Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell. Physiol., 159, 245-255.
89. Kerbel, R.S. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13, 31-36.
90. Kerbel, R.S. (1999) Acquired drug resistance driven by tumor cell genetic-instability: circumvention by direct acting anti-angiogenic vascular targeting agents. In Ehrlich, M. (ed.) DNA Alterations in Cancer: Genetic and Epigenetic Changes. Biotechniques Books, Natick, MA, pp. 489-501.
91. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M.S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-407.
92. Kolata, G. (1998) A cautious awe greets drugs that eradicate tumors in mice. The New York Times, May 3, 1998.
93. Marshall, E. (1998) The power of the front page of The New York Times. Science, 280, 996-997.
94. Kaye, S.B. (1998) Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr. Opin. Oncol., 10 (Suppl. 1), S15-S19.
95. Houghton, P.J. and Kaye, S.B. (1994) Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J. NIH Res., 6, 55.
96. Tannock, I.F. (1998) Conventional cancer therapy: promise broken or promise delayed? Lancet, 351 (Suppl. 2), S119-S116.
97. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 10, 560-565.
98. Browder, T., Butterfield, C.E., Kraling, B.M., Marshall, B., O'Reilly, M.S. and Folkman, J. (1999) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., in press.
99. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P. and Kerbel, R.S. (2000) Chronically sustained regressions of human tumor xenografts in the absence of overt toxicity by continuous low-dose vinblastine and anti-VEGF Receptor-2 antibody therapy. J. Clin. Invest., in press.
100. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R.K. and Seed, B. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell, 94, 715-725.
101. Jain, R.K. (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl Cancer Inst., 81, 570-576.
102. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol., 150, 815-820.
103. Rajkumar, S.V., Fonseca, R., Witzig, T.E., Gertz, M.A. and Greipp, P.R. (1999) Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia, 13, 469-472.
104. Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M. and Dammacco, F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer, 79, 965-970.
105. D'Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA, 91, 4082-4085.
106. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Robertson, P., Eddelmon, P., Munshi, N., Anassie, E., Wilson, C., Dhodapkar, M., Zeldis, J. and Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Meet., 341, 1565-1571.
107. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M.R., Viale, G., Giavazzi, R. and Taraboletti, G. (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2, 1843-1849.
108. Burt, H.M., Jackson, J.K., Bains, S.K., Liggins, R.T., Oktaba, A.M.C., Arsenault, A.L. and Hunter, W.L. (1995) Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (D,L-lactic acid). Cancer Letts, 88, 73-79.
109. Chaplin, D.J., Pettit, G.R., Parkins, C.S. and Hill, S.A. (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer, 74 (Suppl. 27). S86-S88.
110. O'Leary, J.J., Shapiro, R.L., Ren, C.J., Chuang, N., Cohen, H.W. and Potmesil, M. (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan and CPT-11 studied in the mouse cornea model. Clin. Cancer Res., 5, 181-187.
111. Presta, M., Rusnati, M., Belleri, M., Morbidelli, L., Ziche, M. and Ribatti, D. (1999) Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res., 59, 2417-2424.
112. Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba, M.J., Stellato, K.A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W. and Weichselbaum, R.R. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394, 287-291.
113. Jain, R.K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F. and Keshet, E. (1998) Endothelial cell death, angiogenesis and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad, Sci. USA, 95, 10820-10825.
114. Joseph, I.B.J.K., Nelson, J., Denmeade, S.R. and Isaacs, J.T. (1999) Androgens regulate vascular endolhlelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res., 3, 2507-2511.
115. Denekamp, J. (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol., 66, 181-196.
116. Nor, J.E., Christensen, J., Mooney, D.J. and Polverini, P.J. (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol., 154, 375-381.
117. Gerber, H.P. Dixit, V. and Ferrara, N. (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem., 273, 13313-13316.
118. Gerber, H.P. McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V. and Ferrara, N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem., 273, 30336-30343.
119. Carmeliet, P., Lampugnani, M.G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oostuyse, B., Dewerchin, M., Zanetti, A., Angellilo, A., Mattot, V., Nuyens, D., Lutgens, E., Clotman, F., duRuiter, M.C., Gittenberger-de, G.A., Poelmann, R., Lupu, F., Herbert, J.M., Collen, D. and Dejana, E. (1999) Targeted deficiency orcytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell, 98, 147-157.
120. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. and Marme, D. (1995) Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem., 270, 25915-25919.
121. Kerbel, R.S. and Hawley, R.G. (1995) Interleukin 12: newest member of the antiangiogenesis club. J. Natl Cancer Inst., 87, 557-559.
122. Teicher, B.A. (1999) Potentiation of cytotoxic cancer therapies by antiangiogenic agents. In Teicher, B.A. (ed.) Antiangiogenic Agents in Cancer Therapy. Humana Press Inc., Totowa, NJ. pp. 277-316.
123. Teicher, B.A., Dupuis, N.P., Robinson, M.F., Emi, Y. and Goff, D.A. (1995) Antiangiogenic trealment (TNP-4670/minocycline) increases tissue levels of anticancer drugs in mice hearing Lewis lung carcinoma. Oncog. Res., 7, 237-243.
124. Borgstrom, P., Hillan, K.J., Sriramarao, P. and Ferrara, N. (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravilal videomicroscopy. Cancer Res., 56, 4032-4039.
125. Iyer, S., Chaplin, D.J., Rosenthal, D.S., Boulares, A.H., Li, L.Y. and Smulson, M.E. (1998) Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res., 58, 4510-4514.
126. Offodile, R., Walton, T., Lee, M., Stiles, A. and Nguyen, M. (1999) Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori, 85, 51-53.
127. Gelmon, K., Eisenhauer, E., Harris, A.L., Ratain, M.J. and Workman, P. (1999) Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development. J. Natl Cancer Inst., 91, 1281-1287.
128. Kudelka, A.P., Verschraegen, C.F. and Loyer, E. (1998) Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med., 338, 991-992.
129. Gradishar, W.J. (1999) Endpoints for determination of efficacy of antiangiogenicagents in clinical trials. In Teicher, B.A. (ed.) Antiangiogenic Agents in Cancer Therapy, Humana Press Inc., Totowa, NJ, pp. 341-353.
130. Kaban, L.B., Mulliken, J.B., Ezekowitz, R.A., Phil, D., Ebb, D., Smith, P.S. and Folkman, J. (1999) Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics, 103, 1145-1149.
131. Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A. and Slamon, D.J. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16, 2659-2671.
132. Baguley, B.C., Holdaway, K.M., Thomsen, L.L., Zhuang, L. and Zwi, L.J. (1991) Inhibition of growth of colon 38 adenocarcinnma by vinblastine and colchicine: evidence for a vascular mechanism. Eur.J. Cancer, 27, 482-487.
133. Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R. and Chaplin, D.J. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57, 1829-1834.
134. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S. and Thorpe, P.E. (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275, 547-550.
135. Pham, C.D., Roberts, T.P., van Bruggen, N., Melnyk, O., Mann, J., Ferrara, N., Cohen, R.L. and Brasch, R.C. (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest., 16, 225-230.
136. Wu, C.C., Lee, C.N., Chen, T.M., Shyu, M.K., Hsieh, C.Y., Chen, H.Y. and Hsieh, F.J. (1994) Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer, 73, 1251-1256.
137. Cohen, F.M., Kuwatsuru, R., Shames, D.M., Neuder, M., Mann, J.S., Vexler, V., Rosenau, W. and Brasch, R.C. (1994) Contrast-enhanced magnetic-resonance imaging estimation of altered capillary permeability in experimental mammary carcinomas after X-irradiation. Invest. Radiol., 29, 970-977.
138. Pham, C.D., Roberts, T.P., van Bruggen, N., Melnyk, O., Mann, J., Ferrara, N., Cohen, R.L. and Brasch, R.C. (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest., 16, 225-230.
139. Frouge, C., Guinebretiere, J.M., Contesso, G., Di Paola, R. and Blery, M. (1994) Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest. Radiol., 29, 1043-1049.
140. Barlow, C.F., Priebe, C.J., Mulliken, J.B., Barnes, P.D., Mac, D.D., Folkman, J. and Ezekowitz, R.A. (1998) Spastic diplegia as a complication of interferon α-2a treatment of hemangiomas of infancy. J. Pediatr, 132, 527-530.
141. Gerber, H.P. Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.A., Rangell, L., Wright, B.D., Radtke, F., Aguet, M. and Ferrara, N. (1999) VEGF is required for growth and survival in neonatal mice. Development, 126, 1149-1159.
142. Auerbach, R., Alby, L., Morrissey, L.W., Tu, M. and Joseph, J. (1985) Expression of organ-specific antigens on capillary endothelial cells. Microvas. Res., 29, 401-411.
143. Folkman, J. (1999) Angiogenic zip code. Nature Biotechnol., 17, 749.
144. Zhu, D.Z. and Pauli, B.U. (1991) Generation of monoclonal antibodies directed against organ-specific endothelial cell surface determinants. J. Histochem. Cytochem., 39, 1137-1142.
145. Field, S.B., Needham, S., Burney, I.A., Maxwell, R.J., Coggle, J.E. and Griffiths, J.R. (1991) Differences in vascular response between primary and transplanted tumours. Br. J. Cancer, 63, 723-726.
146. Chishima, T., Miyagi, Y., Wang, X., Yamaoka, H., Shimada, H., Moossa, A.R. and Hoffman, R.M. (1997) Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res., 37, 2042-2047.
147. Edinger, M., Sweeney, T.J., Tucker, A.A., Olomu, A.B., Negrin, R.S. and Contag, C.H. (1999) Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia, 1, 303-310.
148. Killion, J.J., Radinsky, R. and Fidler, I.J. (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev., 17, 279-284.
149. Willmanns, C., Fan, D., O'Brian, C.A., Radinsky, R., Bucana, C.D., Tsan, R. and Fidler, I.J. (1993) Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinomacells by ectopic and ortholopic environments in nude mice. Int. J. Cancer, 3, 412-122.
150. Wilmanns, C., Fan, D., O'Brian, C.A., Bucana, C.D. and Fidler, I.J. (1992) Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int. J. Cancer, 52, 98-104.
151. Parangi, S., O'Reilly, M.S., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J. and Hanahan, D. (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl Acad. Sci. USA, 93, 2002-2007.
152. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J. and Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808-812.
153. Dexter, D.L., Diamond, M., Creveling, J. and Chen, S.F. (1993) Chemotherapy of mammary carcinomas arising in rax transgenic mice. Invest. New Draw, 11, 161-168.
154. Meier, P. and Evan, G. (1998) Dying like flies. Cell, 95, 295-298.
155. Kerr, J.F., Winterford, C.M. and Harmon, B.V. (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
156. Kong, H.L. and Crystal, R.G. (1998) Gene therapy strategies for tumor antiangiogenesis. J. Natl Cancer Inst., 90, 273-286.
157. Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R. and Min, W. (1999) Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Bioiechnol., 17, 343-348.
158. Schumacher, B., Pecher, P. von Specht, B.U. and Stegmann, T. (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation, 97, 645-650.
159. Isner, J.M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K. and Symes, J.F. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet, 348, 370-374.
160. Matsuzaki, S., Canis, M., Darcha, C., Dechelotte, P., Pouly, J.L. and Bruhat, M.A. (1998) Angiogenesis in endometriosis, Gynecol. Obstet. Invest., 46, 111-115.
161. Isner, J.M. (1999) Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation, 99, 1653-1655.
162. Moulton, K.S., Heller, E., Konerding, M.A., Flynn, E., Palinski, W. and Folkman, J. (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation, 99, 1726-1732.
163. Ji, W.R., Barrientos, L.G., Llinas, M., Gray, H., Villarreal, X., DeFord, M.E., Castellino, F.J., Kramer, R.A. and Trail, P.A. (1998) Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun., 247, 414-419.
164. Cao, Y., Chen, A., An, S.S.A., Ji, R.W., Davidson, D. and Llinas, M. (1997) Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem., 272, 22924-22928.
165. Ramchandran, R., Dhanabal, M., Volk, R., Waterman, M.J., Segal, M., Lu, H., Knebelmann, B. and Sukhatme, V.P. (1999) Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison with endostatin. Biochem. Biophys. Res. Commun., 255, 735-739.
166. Jackson, D., Volpert, O.V., Bouck, N. and Linzer, D.I. (1994) Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science, 266, 1581-1584.